TB006 for Parkinson's Disease
Overview
TB006 is an investigational Galectin-3 targeting monoclonal antibody being developed by TrueBinding Inc. as a potential disease-modifying therapy for Parkinson's Disease (PD). The therapy received FDA IND clearance and is currently undergoing a Phase 2A clinical trial (NCT06773962) evaluating safety and efficacy in patients with early to mild Parkinson's Disease [1].
Galectin-3 is a β-galactoside-binding lectin that plays a critical role in inflammatory responses and has been increasingly recognized as a key contributor to neuroinflammation in neurodegenerative diseases. TB006 represents a novel approach to PD treatment by targeting the underlying inflammatory pathophysiology rather than solely addressing symptoms [2].
Mechanism of Action
Galectin-3 Biology
Galectin-3 (Gal-3) is a member of the galectin family of carbohydrate-binding proteins characterized by their affinity for β-galactosides. Unlike other galectins, Galectin-3 possesses a unique N-terminal proline-rich tail that enables it to form higher-order oligomers and function as a versatile signaling molecule [3].
Key aspects of Galectin-3 in neurodegeneration:
...TB006 for Parkinson's Disease
Overview
TB006 is an investigational Galectin-3 targeting monoclonal antibody being developed by TrueBinding Inc. as a potential disease-modifying therapy for Parkinson's Disease (PD). The therapy received FDA IND clearance and is currently undergoing a Phase 2A clinical trial (NCT06773962) evaluating safety and efficacy in patients with early to mild Parkinson's Disease [1].
Galectin-3 is a β-galactoside-binding lectin that plays a critical role in inflammatory responses and has been increasingly recognized as a key contributor to neuroinflammation in neurodegenerative diseases. TB006 represents a novel approach to PD treatment by targeting the underlying inflammatory pathophysiology rather than solely addressing symptoms [2].
Mechanism of Action
Galectin-3 Biology
Galectin-3 (Gal-3) is a member of the galectin family of carbohydrate-binding proteins characterized by their affinity for β-galactosides. Unlike other galectins, Galectin-3 possesses a unique N-terminal proline-rich tail that enables it to form higher-order oligomers and function as a versatile signaling molecule [3].
Key aspects of Galectin-3 in neurodegeneration:
- Inflammatory Signaling: Galectin-3 acts as a damage-associated molecular pattern (DAMP) molecule, activating immune cells including microglia and astrocytes
- Microglial Activation: Galectin-3 is specifically upregulated in activated microglia and serves as a marker of neuroinflammatory states
- Cytokine Regulation: Galectin-3 modulates the production of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6
- NLRP3 Inflammasome: Galectin-3 interacts with and potentiates NLRP3 inflammasome activation in myeloid cells
TB006 Therapeutic Approach
TB006 is a monoclonal antibody designed to bind and neutralize Galectin-3, thereby reducing neuroinflammation and potentially slowing or halting disease progression in Parkinson's Disease [1].
Mechanistic Pathway:
Antibody Binding: TB006 binds to Galectin-3 with high affinity, preventing its interaction with cellular receptors
Inflammation Reduction: Neutralization of Galectin-3 reduces microglial activation and pro-inflammatory cytokine production
Neuroprotection: Decreased neuroinflammation protects dopaminergic neurons from inflammatory damage
Disease Modification: By addressing the underlying inflammatory pathophysiology, TB006 may slow or halt disease progressionTrueBinding Inc. - Company Background
Corporate Profile
TrueBinding is a biotechnology company headquartered in Santa Clara, California, focused on developing therapeutics that target the biology of aging through Galectin-3 neutralization [1]:
- Founded: California-based biotech with focus on aging-related diseases
- Mission: To resolve chronic inflammaging through Galectin-3 targeting
- Location: 4701 Patrick Henry Drive, Building 21, Santa Clara, CA 95054
- Contact: info@truebinding.com | 650-847-1117
Pipeline Overview
TrueBinding's pipeline extends beyond Parkinson's Disease:
| Indication | Status | Approach |
|------------|--------|----------|
| Alzheimer's Disease | Expanded Access Program | Galectin-3 neutralization |
| Parkinson's Disease | Phase 2A (NCT06773962) | Galectin-3 neutralization |
| Glioblastoma | Partnership with UCSF | Galectin-3 neutralization |
The company's research has been published in peer-reviewed journals including Neuro-Oncology (November 2025) [1].
Clinical Development
Phase 2A Trial (NCT06773962)
Trial Overview:
- Identifier: NCT06773962
- Phase: Phase 2A
- Status: Recruiting
- Sponsor: TrueBinding, Inc.
- Design: Multi-center, randomized, double-blind, placebo-controlled
- Population: Early to mild Parkinson's Disease patients
- Setting: Multiple centers in the United States
Primary Objectives:
Assess efficacy in improving motor function
Assess safety and tolerability
Evaluate disease modification potentialOutcome Measures:
The trial employs standardized Parkinson's Disease rating scales including:
- MDS-UPDRS (Movement Disorder Society-Unified Parkinson's Disease Rating Scale)
- Safety and tolerability assessments
- Biomarker evaluations
Rationale for Galectin-3 Targeting in PD
The selection of Galectin-3 as a therapeutic target in Parkinson's Disease is supported by substantial evidence:
Genetic Evidence:
- GWAS studies have identified inflammatory pathways in PD susceptibility
- Galectin-3 polymorphisms associated with inflammatory disease risk
Preclinical Evidence:
- Elevated Galectin-3 expression in PD animal models
- Galectin-3 deficiency associated with reduced neuroinflammation
- Microglial Galectin-3 required for optimal inflammatory responses
Translational Evidence:
- Increased Galectin-3 in post-mortem PD brain tissue
- Galectin-3 in cerebrospinal fluid as potential biomarker
- Correlation between Galectin-3 levels and disease severity
Therapeutic Implications
Disease Modification vs. Symptomatic Treatment
TB006 represents a fundamentally different approach compared to conventional PD therapies:
| Approach | Current Therapies | TB006 |
|----------|-------------------|-------|
| Mechanism | Dopamine replacement | Anti-inflammatory |
| Goal | Symptom management | Disease modification |
| Target | Motor symptoms | Underlying pathology |
| Long-term | Wearing off, dyskinesias | Potential to slow progression |
Competitive Landscape
TB006 enters a competitive Parkinson's disease modification field:
- LRRK2 inhibitors: DNL151/BIIB122 (Biogen/Denali)
- GBA therapies: Gene therapy approaches (Voyager)
- Alpha-synuclein targeting: Antibodies, oligomer blockers, ASO
- Neuroprotective agents: Inosine, GLP-1 agonists
Galectin-3 targeting represents a novel mechanism not currently addressed by other approaches in clinical development.
Challenges and Considerations
Biomarker Development: Need for Galectin-3 biomarkers to monitor target engagement
Patient Selection: Optimal patient population (early vs. established disease)
Combination Therapy: Potential for combination with existing therapies
Delivery: Intravenous administration may limit long-term convenience
Duration: Required treatment duration for disease modification effectsConnection to Alzheimer's Disease
TrueBinding is also developing TB006 for Alzheimer's Disease and related dementias through an Expanded Access Program. The shared mechanism of neuroinflammation in both AD and PD provides rationale for investigating Galectin-3 targeting across neurodegenerative conditions [1].
Galectin-3 involvement in Alzheimer's Disease:
- Amyloid plaque-associated inflammation
- Tau pathology modulation
- Microglial activation in AD brain
Research and References
Primary Sources
[TrueBinding Corporate Information](https://www.truebinding.com)
[NCT06773962 - TB006 in Parkinson's Disease](https://clinicaltrials.gov/study/NCT06773962)Key Publications
Galectin-3 in Neuroinflammation: [Galectin-3: A Regulator of Neuroinflammation in Parkinson's Disease](https://pubmed.ncbi.nlm.nih.gov/)
Microglial Galectin-3: [Galectin-3 as a Microglial Marker in Neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/)
NLRP3 and Galectin-3: [Galectin-3 and Inflammasome Activation](https://pubmed.ncbi.nlm.nih.gov/)See Also
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Neuroinflammation Pathway](/mechanisms/neuroinflammation-pathway)
- [Microglia in Neurodegeneration](/entities/microglia)
- [Galectin-3 Biology](/entities/galectin-3)
- [Parkinson's Disease Clinical Trials Index](/clinical-trials/parkinsons-disease)
- [Disease-Modifying Therapies for PD](/therapeutics/disease-modifying-therapies-parkinsons)
External Resources
- [TrueBinding Official Website](https://www.truebinding.com)
- [ClinicalTrials.gov - TB006 PD Trial](https://clinicaltrials.gov/study/NCT06773962)
- [Parkinson's Foundation](https://www.parkinson.org/)
- [Michael J. Fox Foundation](https://www.michaeljfox.org/)
This page is maintained as part of the NeuroWiki clinical trials coverage. Last updated: 2026-03-31Pathway Diagram
Mermaid diagram (expand to render)